Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356 · ADVANCED-3 Phase 3Recruiting
- Lead sponsor
- Protara Therapeutics (Industry)
- Enrollment
- 284 (estimated)
- Start date
- 29 May 2026
- Primary completion
- Apr 2028 (estimated)
- Study completion
- 1 Nov 2032
- Last update posted
- 6 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- TARA-002 Drug
- Investigator's Choice of Intravesical Chemotherapy Drug
Conditions and primary outcome
- Bladder (Urothelial, Transitional Cell) Cancer
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Primary outcome
Incidence of high-grade complete response (Month 6)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07480356.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07480356 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.